Connection

HUDA ZOGHBI to Peptides

This is a "connection" page, showing publications HUDA ZOGHBI has written about Peptides.
Connection Strength

3.328
  1. Pathogenesis of polyglutamine diseases: Piecing together a complex molecular puzzle. J Exp Med. 2026 Jan 05; 223(1).
    View in: PubMed
    Score: 0.717
  2. Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. J Biol Chem. 2009 Mar 20; 284(12):7425-9.
    View in: PubMed
    Score: 0.221
  3. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature. 2008 Apr 10; 452(7188):713-8.
    View in: PubMed
    Score: 0.211
  4. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. Hum Mol Genet. 2005 Mar 01; 14(5):679-91.
    View in: PubMed
    Score: 0.170
  5. Cross-species genetic screens identify transglutaminase 5 as a regulator of polyglutamine-expanded ataxin-1. J Clin Invest. 2022 05 02; 132(9).
    View in: PubMed
    Score: 0.141
  6. SCA1 molecular genetics: a history of a 13 year collaboration against glutamines. Hum Mol Genet. 2001 Oct 01; 10(20):2307-11.
    View in: PubMed
    Score: 0.135
  7. Modulation of ATXN1 S776 phosphorylation reveals the importance of allele-specific targeting in SCA1. JCI Insight. 2021 02 08; 6(3).
    View in: PubMed
    Score: 0.129
  8. Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1. Nat Neurosci. 2000 Feb; 3(2):157-63.
    View in: PubMed
    Score: 0.121
  9. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron. 1999 Dec; 24(4):879-92.
    View in: PubMed
    Score: 0.119
  10. Expanding our understanding of polyglutamine diseases through mouse models. Neuron. 1999 Nov; 24(3):499-502.
    View in: PubMed
    Score: 0.118
  11. Polyglutamine diseases: protein cleavage and aggregation. Curr Opin Neurobiol. 1999 Oct; 9(5):566-70.
    View in: PubMed
    Score: 0.118
  12. PAK1 regulates ATXN1 levels providing an opportunity to modify its toxicity in spinocerebellar ataxia type 1. Hum Mol Genet. 2018 08 15; 27(16):2863-2873.
    View in: PubMed
    Score: 0.109
  13. The CAG/polyglutamine tract diseases: gene products and molecular pathogenesis. Brain Pathol. 1997 Jul; 7(3):927-42.
    View in: PubMed
    Score: 0.101
  14. Toward understanding polyglutamine-induced neurological disease in spinocerebellar ataxia type 1. Cold Spring Harb Symp Quant Biol. 1996; 61:649-57.
    View in: PubMed
    Score: 0.091
  15. Polyglutamine disease toxicity is regulated by Nemo-like kinase in spinocerebellar ataxia type 1. J Neurosci. 2013 May 29; 33(22):9328-36.
    View in: PubMed
    Score: 0.076
  16. Duplication of Atxn1l suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes. Nat Genet. 2007 Mar; 39(3):373-9.
    View in: PubMed
    Score: 0.049
  17. Trinucleotide repeat disorders. Annu Rev Neurosci. 2007; 30:575-621.
    View in: PubMed
    Score: 0.049
  18. ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell. 2006 Dec 29; 127(7):1335-47.
    View in: PubMed
    Score: 0.049
  19. Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet. 2005 Oct; 6(10):743-55.
    View in: PubMed
    Score: 0.045
  20. SUMOylation of the polyglutamine repeat protein, ataxin-1, is dependent on a functional nuclear localization signal. J Biol Chem. 2005 Jun 10; 280(23):21942-8.
    View in: PubMed
    Score: 0.043
  21. The effects of the polyglutamine repeat protein ataxin-1 on the UbL-UBA protein A1Up. J Biol Chem. 2004 Oct 01; 279(40):42290-301.
    View in: PubMed
    Score: 0.041
  22. Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell. 2003 May 16; 113(4):457-68.
    View in: PubMed
    Score: 0.038
  23. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron. 2003 May 08; 38(3):375-87.
    View in: PubMed
    Score: 0.038
  24. Enhanced SUMOylation in polyglutamine diseases. Biochem Biophys Res Commun. 2002 Apr 26; 293(1):307-13.
    View in: PubMed
    Score: 0.035
  25. The spinocerebellar ataxia type 1 protein, ataxin-1, has RNA-binding activity that is inversely affected by the length of its polyglutamine tract. Hum Mol Genet. 2001 Jan 01; 10(1):25-30.
    View in: PubMed
    Score: 0.032
  26. Fourteen and counting: unraveling trinucleotide repeat diseases. Hum Mol Genet. 2000 Apr 12; 9(6):909-16.
    View in: PubMed
    Score: 0.031
  27. Reversing neurodegeneration: a promise unfolds. Cell. 2000 Mar 31; 101(1):1-4.
    View in: PubMed
    Score: 0.030
  28. Glutamine repeats and neurodegeneration. Annu Rev Neurosci. 2000; 23:217-47.
    View in: PubMed
    Score: 0.030
  29. Trinucleotide repeats: mechanisms and pathophysiology. Annu Rev Genomics Hum Genet. 2000; 1:281-328.
    View in: PubMed
    Score: 0.030
  30. Progress in pathogenesis studies of spinocerebellar ataxia type 1. Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29; 354(1386):1079-81.
    View in: PubMed
    Score: 0.029
  31. Pathogenesis of polyglutamine-induced disease: A model for SCA1. Mol Genet Metab. 1999 Mar; 66(3):172-8.
    View in: PubMed
    Score: 0.028
  32. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet. 1997 Jan; 15(1):62-9.
    View in: PubMed
    Score: 0.024
  33. Cerebellar Transcriptome Profiles of ATXN1 Transgenic Mice Reveal SCA1 Disease Progression and Protection Pathways. Neuron. 2016 Mar 16; 89(6):1194-1207.
    View in: PubMed
    Score: 0.023
  34. A native interactor scaffolds and stabilizes toxic ATAXIN-1 oligomers in SCA1. Elife. 2015 May 19; 4.
    View in: PubMed
    Score: 0.022
  35. Partial loss of Tip60 slows mid-stage neurodegeneration in a spinocerebellar ataxia type 1 (SCA1) mouse model. Hum Mol Genet. 2011 Jun 01; 20(11):2204-12.
    View in: PubMed
    Score: 0.016
  36. Characterization of the zebrafish atxn1/axh gene family. J Neurogenet. 2009; 23(3):313-23.
    View in: PubMed
    Score: 0.014
  37. CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. J Biol Chem. 2006 Sep 08; 281(36):26714-24.
    View in: PubMed
    Score: 0.012
  38. Glutamine-expanded ataxin-7 alters TFTC/STAGA recruitment and chromatin structure leading to photoreceptor dysfunction. PLoS Biol. 2006 Mar; 4(3):e67.
    View in: PubMed
    Score: 0.011
  39. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J Neurosci. 2004 Oct 06; 24(40):8853-61.
    View in: PubMed
    Score: 0.010
  40. Amino acids in a region of ataxin-1 outside of the polyglutamine tract influence the course of disease in SCA1 transgenic mice. Neuromolecular Med. 2002; 1(1):33-42.
    View in: PubMed
    Score: 0.009
  41. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell. 1998 Oct 02; 95(1):41-53.
    View in: PubMed
    Score: 0.007
  42. Identification of a self-association region within the SCA1 gene product, ataxin-1. Hum Mol Genet. 1997 Apr; 6(4):513-8.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.